Personal Finance

What's Next For Celgene


Celgene Corp. 's(NASDAQ: CELG) management took to the stage at the annual JP Morgan healthcare conference to outline to industry watchers its plans for the future. The presentation included updates to its financial guidance, and a peek into management's plans for its drug pipeline. Are Celgene's best days ahead of it?


Image source: Celgene Corp.

A bright future

What may make Celgene so confident in its future could be a patent portfolio that protects its top sellers deep into the 2020s. For instance, Revlimid's patents protect it in the U.S. until 2027, and Otezla's patents protect it until 2024, and possibly until 2028, depending on how a patent expansion attempt pans out.

In the short-term, investors may reward or punish Celgene's shares based on ozanimod's phase 3 outcome this year. However, Celgene can still successfully grow sales and earnings without ozanimod, and its pipeline is packed full of promising therapies that could still move shares higher, regardless of ozanimod's outcome. For that reason, Celgene remains one of the most dynamic and attractive investments in this high-growth industry, and a core holding deserving of a spot in biotech investor's portfolios.

10 stocks we like better than Celgene

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Celgene wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of January 4, 2017

Todd Campbell owns shares of Celgene. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned.Like this article? Follow him on Twitter where he goes by the handle @ebcapitalto see more articles like this. The Motley Fool owns shares of and recommends Celgene. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More